What is the current stock price of Hofseth BioCare ASA (HOFBF)?

As of the latest market data, Hofseth BioCare ASA (HOFBF) is trading at $0.17. The stock has seen a loss of 0.00% today.

Does Hofseth BioCare ASA (HOFBF) pay a dividend?

Based on current data, Hofseth BioCare ASA does not have a confirmed active dividend policy.

What is the market cap of Hofseth BioCare ASA?

The current market capitalization of Hofseth BioCare ASA (HOFBF) is approximately unavailable.

HOFBF

Hofseth BioCare ASA·Healthcare

0.17

0.000%(+0.00)

Close Price

Last Updated: — ET

52W L: $0.1552W H: $0.18

HOFBF NEWS

globenewswire.com

6d ago

Hofseth BioCare ASA: EXCLUSIVE LICENSE AND SUPPLY AGREEMENT SIGNED FOR PROGO FOR OVER $5M

Hofseth BioCare ASA (“HBC”) has entered into an Exclusive License and Supply Agreement (the “Agreement”) with Fission Holdings LLC (“Fission”), a US-based affiliate and sales channel operator headquartered in Tulsa, Oklahoma. The Agreement grants Fission exclusive worldwide rights to import, market, distribute, and sell HBC's ProGo® salmon-derived bioactive peptide ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel.

globenewswire.com

Apr 14

Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas

HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a popular omega-3 supplement brand. It was also markedly more effective at reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related to the development of ill health.

globenewswire.com

Mar 27

Hofseth BioCare ASA: HBC ANNUAL REPORT 2025

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2025, and HBC has today published the Annual Report and Sustainability Report for 2025. In October 2025, the Company announced a successful placing of new ordinary shares with gross proceeds of NOK 158 million. As of the date of this Annual report, the Company has yet to receive all share deposits and has therefore not completed the transaction. The primary cause of the delay is stated to be of a technical and legal nature relating to the main investor who has repeatedly expressed its intention to swiftly complete the transaction. The Board therefore expects the transaction to be completed in Q2 2026. The proceeds of the transaction will materially strengthen the Company's balance sheet and support ongoing growth momentum.

Company Profile

Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; CalGo, a marine calcium powder produced to support cartilage function and joint health; CollaGo, a collagen peptide powder to enhance the beauty of hair, skin, and nails; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. It has a research agreement with Stanford University School of Medicine for pre-clinical and clinical research on necrotizing enterocolitis and irritable bowel syndrome. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-08-22

Beta

0.25

Websitewww.hofsethbiocare.no↗